Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: Interactive Journal of Medical Research

Date Submitted: Jul 31, 2022
Open Peer Review Period: Jul 31, 2022 - Sep 25, 2022
Date Accepted: Apr 7, 2023
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Cardiovascular Risk Assessment Among Adolescents and Youths Living With HIV: Evaluation of Electronic Health Record Findings and Implications

Gurung S, Simpson KN, Grov C, Rendina HJ, Huang TTK, Budhwani H, Jones SS, Dark T, Naar S

Cardiovascular Risk Assessment Among Adolescents and Youths Living With HIV: Evaluation of Electronic Health Record Findings and Implications

Interact J Med Res 2023;12:e41574

DOI: 10.2196/41574

PMID: 37585242

PMCID: 10468705

Cardiovascular Risk Assessment Among Adolescents and Youth Living with HIV: Electronic Health Record Findings and Implications

  • Sitaji Gurung; 
  • Kit N. Simpson; 
  • Christian Grov; 
  • H. Jonathon Rendina; 
  • Terry T-K Huang; 
  • Henna Budhwani; 
  • Stephen Scott Jones; 
  • Tyra Dark; 
  • Sylvie Naar

ABSTRACT

Background:

The relationship between HIV-related biomarkers and cardiovascular risk among youth living with HIV (YLH) is understudied.

Objective:

Considering this gap, we examined whether detectable viral load (VL) and low CD4, indications of unsuppressed HIV, were associated with cardiovascular risk among YLH.

Methods:

We analyzed electronic health record data from 7 adolescent HIV clinics in the United States (N=813 YLH). Multivariable linear regression was used to assess the association of detectable VL and CD4 ≤ 200 with cardiovascular risk scores adapted from the Framingham gender-specific algorithm.

Results:

Nearly half of participants (47.8%) had detectable VL, indicating unsuppressed HIV, and 8.6% had CD4≤ 200, indicating impaired immune function. Cardiovascular risk was significantly increased in patients with CD4≤ 200 compared to those with CD4>200, as measured by Cardiac Risk Score 2 (p< 0.01). After adjusting for demographic and clinical covariates, we found that for a 1000-point increase in VL copies/mL, there was a 38% increase in the likelihood of having cardiovascular risk (Cardiac Risk Score 2). A small effect was observed for VL on increased cardiovascular risk when measuring the strength of this association (β=0.134, SE=0.014, p<0.01). We observed similar findings with Cardiac Risk Score 1 but the effect of CD4≤ 200 was no longer significant.

Conclusions:

Our findings indicate that detectable VL is associated with cardiovascular risk among YLH. Multi-component interventions that promote VL suppression, while concurrently targeting cardiovascular risk reduction, among YLH are warranted. If tailored specifically for youth, such an integrated approach could improve the overall well-being across the HIV continuum of care and over the life course.


 Citation

Please cite as:

Gurung S, Simpson KN, Grov C, Rendina HJ, Huang TTK, Budhwani H, Jones SS, Dark T, Naar S

Cardiovascular Risk Assessment Among Adolescents and Youths Living With HIV: Evaluation of Electronic Health Record Findings and Implications

Interact J Med Res 2023;12:e41574

DOI: 10.2196/41574

PMID: 37585242

PMCID: 10468705

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.